ProfileGDS5678 / 1460745_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 31% 32% 32% 30% 33% 30% 30% 35% 53% 31% 32% 33% 32% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7384831
GSM967853U87-EV human glioblastoma xenograft - Control 22.7272932
GSM967854U87-EV human glioblastoma xenograft - Control 32.7245432
GSM967855U87-EV human glioblastoma xenograft - Control 42.6409730
GSM967856U87-EV human glioblastoma xenograft - Control 52.7066833
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7493230
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7265530
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7829135
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2721253
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6910431
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7126632
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7095733
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7253432
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7180132